AI-ML-enabled-real-world-evidenceRWE-analytics-1

AI/ML-enabled RWE analytics

Augment value for pharma and medical devices by analyzing real-world evidence (RWE) across the product life cycle.

Real-world evidence

RWE rises to support clinical inferences on treatment efficacies. The information from electronic health records (EHR) and electronic medical records (EMR) along with other patient treatment records is compelling to guide companies, physicians, and the managed care ecosystem to deliver truly benefitting patient outcomes. Razor-sharp data and analytics capabilities are crucial for harvesting real-world data (RWD) and delivering evidence-based assessments across the healthcare value continuum.

Axtria’s experience with RWE data management, along with its AI/ML RWE models help healthcare stakeholders generate and demonstrate value and meet growing evidence generation requirements.

Download Report / The Economic Value Of Insulin Glargine 300 U/Ml (GLA-300) In People ≥18 Years Of Age With Type 2 Diabetes Mellitus

Download Report / HEOR value demonstration and evidence generation challenges

AI-driven solution applications

AI/ML models to quantify the magnitude of misdiagnosed patients for targeted intervention.

New product insights into market access through patient sub-population model.

Identifying “biologic-ready” patients for better insights into the overall disease burden.

Drivers for evidence-based demonstrations across the product life cycle

Pre-launch

Unmet needs and disease burden
Patient recruitment
Understand the standard of care
Clinical trial design

Launch and scale

Patient safety
Product comparative effectiveness
Patient adherence
Prescribing patterns
Differentiation in sub-populations
Long-term clinical outcomes
Target population implications

Loss-of-exclusivity (LOE)

Effects of switching on outcomes
Usage differences
Differentiate with or vs. protected formulation

For payers to deliver cost-effective care coverage and value for patients’ money.
For providers to identify better ways to manage patient health.
For life sciences organizations to make better decisions related to pre-launch, market access, and commercialization.